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Vascular Medicine
Elevated Levels of Inflammatory Cytokines Predict Survival
in Idiopathic and Familial Pulmonary Arterial Hypertension
Elaine Soon, MRCP, MBBChir*; Alan M. Holmes, PhD*; Carmen M. Treacy, BSc;
Natalie J. Doughty, MSc; Laura Southgate, PhD; Rajiv D. Machado, PhD;
Richard C. Trembath, FMedSci; Simon Jennings, PhD; Lucy Barker, PhD; Paul Nicklin, PhD;
Christoph Walker, PhD;† David C. Budd, PhD;
Joanna Pepke-Zaba, PhD, FRCP; Nicholas W. Morrell, MD, FRCP
Background—Inflammation is a feature of pulmonary arterial hypertension (PAH), and increased circulating levels of
cytokines are reported in patients with PAH. However, to date, no information exists on the significance of elevated
cytokines or their potential as biomarkers. We sought to determine the levels of a range of cytokines in PAH and to
examine their impact on survival and relationship to hemodynamic indexes.
Methods and Results—We measured levels of serum cytokines (tumor necrosis factor-, interferon- and interleukin-1, -2,
-4, -5, -6, -8, -10, -12p70, and -13) using ELISAs in idiopathic and heritable PAH patients (n60). Concurrent clinical data
included hemodynamics, 6-minute walk distance, and survival time from sampling to death or transplantation. Healthy
volunteers served as control subjects (n21). PAH patients had significantly higher levels of interleukin-1, -2, -4, -6, -8, -10,
and -12p70 and tumor necrosis factor- compared with healthy control subjects. Kaplan-Meier analysis showed that levels
of interleukin-6, 8, 10, and 12p70 predicted survival in patients. For example, 5-year survival with interleukin-6 levels of9
pg/mL was 30% compared with 63% for patients with levels9 pg/mL (P0.008). In this PAH cohort, cytokine levels were
superior to traditional markers of prognosis such as 6-minute walk distance and hemodynamics.
Conclusions—This study illustrates dysregulation of a broad range of inflammatory mediators in idiopathic and familial PAH
and demonstrates that cytokine levels have a previously unrecognized impact on patient survival. They may prove to be useful
biomarkers and provide insight into the contribution of inflammation in PAH. (Circulation. 2010;122:920-927.)
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Idiopathic pulmonary arterial hypertension (PAH) is a devas-tating condition characterized by remodeling of small to
medium-sized pulmonary arteries, leading to elevated pulmo-
nary arterial pressure and ultimately to right heart failure and
death. Our knowledge of the pathogenesis and progression of
idiopathic PAH is still limited. Mutations in the bone morpho-
genetic protein receptor type II (BMPR-II) gene are linked to
susceptibility to both familial and sporadic forms of PAH.1,2
However, because the penetrance of disease for known BMPR2
mutations ranges from 15% to 80%,3 additional “hits” must be
required for initiation of disease. The exact nature of these remains
unclear, but inflammation has been widely implicated.
Clinical Perspective on p 927
There is substantial evidence supporting a role for inflam-
matory cytokines in the development of idiopathic PAH. In
patients with idiopathic PAH, increased circulating levels of
monocyte chemoattractant protein-1, tumor necrosis factor-
(TNF-), interleukin (IL)-1, and IL-64,5 are observed. In-
flammatory infiltrates, consisting of T and B lymphocytes
and macrophages, are described in the plexiform lesions6
characteristic of PAH. Animal models also support the role of
inflammatory cytokines in the initiation and progression of
PAH. For example, IL-6 is consistently elevated in animal
models of experimental PAH.7,8 Transgenic overexpression
of IL-6 leads to severe pulmonary hypertension in mice,9 and
IL-6–deficient mice are protected from hypoxia-driven ex-
perimental pulmonary hypertension.10 There is now increas-
ing evidence for an interaction between BMPR-II and IL-6 in
both in vitro and in vivo models. For example, transgenic
mice overexpressing a dominant-negative BMPR-II demon-
strated increased lung IL-6 expression and enhanced suscep-
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tibility to pulmonary hypertension.11 In addition, increased
IL-6 suppresses the expression of BMPR-II via induction of
a micro-RNA cluster pathway.12 Interestingly, adenoviral
overexpression of IL-10 protects against monocrotaline-
induced pulmonary hypertension in rats.13 Here, we deter-
mined the profile of a broad range of cytokines in patients
with idiopathic and heritable PAH and examined the relation-
ship between these cytokines and the hemodynamics, func-
tional capacity, and survival of these patients.
Methods
Study Subjects
Sixty patients with a confirmed diagnosis of idiopathic or heritable
PAH were prospectively recruited at Papworth Hospital, Cambridge,
UK, from 2001 to 2007. Idiopathic PAH was defined by mean
pulmonary artery pressure of 25 mm Hg at rest with a pulmonary
capillary wedge pressure of 15 mm Hg with no underlying cause
for PAH (Venice classification 1a).14 All patients were screened for
mutations in BMPR-II. Eleven patients had a confirmed mutation in
BMPR-II. One other patient had a family history of PAH but no
mutation in BMPR-II. These 12 were classified as having heritable
PAH and analyzed as a subset. In addition to basic demographics, the
following data were gathered: hemodynamic measurements from the
right heart catheterization (RHC) performed closest to the time of
blood sampling for cytokines; exercise tolerance as measured by the
6-minute walk distance (6MWD) test; survival status at December
31, 2008, and survival time from sampling for cytokines to either
death or transplantation; and exposure to PAH therapy, especially if
the patients were on prostacyclin or prostaglandin analogs.
Sampling for cytokines and measurement of hemodynamics and
6MWD were undertaken after a diagnosis of idiopathic or heritable
PAH was established. Sampling was performed once in each subject and
at various times from diagnosis (mean, 1.422.4 years from diagnosis).
The present study thus represents a series of point measurements of
cytokine levels and clinical parameters in PAH patients who were at
different stages of their disease. Survival time was calculated individu-
ally for each patient as the time period from blood sampling or clinical
measurement to either death or transplantation.
Twenty-one control subjects were selected from a cohort of
healthy volunteers. The mean age of control subjects was 42.013
years, and the ratio of men to women was 1:3. The study was
approved by the local research ethics committee, and all participants
gave informed written consent.
BMPR2 Mutation Analysis
The mutation status of PAH patients was determined as previously
described.15 Briefly, DNA was isolated by standard protocols, and
the protein coding sequence for BMPR2 was amplified from genomic
DNA, together with intron-exon boundaries. Polymerase chain reaction
products were purified with the QIAquick purification kit (Qiagen,
Valencia, Calif) and cycle sequenced with ABI Big Dye terminator on
an ABI PRISM 377 (Applied Biosystems, Foster City, Calif).
Serum Samples and Cytokine Levels
Peripheral venous blood samples were collected, kept on ice, and
centrifuged within 30 minutes. Serum samples were stored at20°C
until analyzed. The system used was single-plex and multiplex
assays manufactured by Meso Scale Discovery (Gaithersburg, Md).
Serum from PAH patients (n60) and control subjects (n21) was
incubated on a multiplex 96-well plate-based assay that contained
antibodies to interferon-, TNF-, IL-1, IL-2, IL-4, IL-5, IL-8,
IL-10, IL-12p70, and IL-13 or a single-plex 384-well plate-based
assay with the IL-6 antibody. Briefly, the Meso Scale Discovery plex
assays were run as follows. Calibration curves were prepared in the
supplied assay diluent for human serum, with a range of 40 000 to
1.2 pg/mL, depending on the cytokine. Arrays were preincubated
with 25 L per well of assay diluent for 30 minutes. After the
preincubation, 25 L sample or calibrator was added in duplicate to
the appropriate wells. The array was then incubated at room
temperature for 2 hours. The array was washed with PBS plus 0.05%
Tween 20, and 25 L detection antibody reagent was added. After 2
hours of incubation at room temperature, the array was washed and the
detection buffer was added. Results were read with a Meso Scale
Discovery Sector Imager 6000. Sample cytokine concentrations were
determined with Softmax Pro Version 4.6 software using curve fit
models.
Statistics
Values in tables are meanSEM. Data were tested for adherence to
a normal distribution with the Kolmogorov-Smirnov method. The
Mann-Whitney test was used to compare nonparametric data, and the
unpaired t test (with Welch correction) was used for parametric data.
The Spearman test was performed for intergroup correlations. In graphs
showing cytokine levels, median values are given. Statistical analysis,
including Kaplan-Meier plotting, log-rank testing, and Cox
proportional-hazard model analysis, was performed with SPSS version
16.0 and Prism 5.0 (SPSS Inc, Chicago, Ill). Kaplan-Meier curves were
constructed on the basis of the quartile values of the parameter being
measured. In addition, an interpolation process was undertaken to select
a single value for cytokine level or hemodynamic parameter that
demonstrated the largest difference for survival curves in between
groups. In addition, the c index16 was calculated to provide additional
information on the most appropriate cutoff points for cytokines. Values
of P0.05 were considered statistically significant.
Results
Table 1 shows the demographics, hemodynamic parameters,
and 6MWD for all patients.
Analysis of Cytokine Profile for All PAH Patients
Eight cytokines, IL-1 (P0.0004), IL-2 (P0.0008), IL-4
(P0.015), IL-6 (P0.0001), IL-8 (P0.0001), IL-12p70
(P0.0489), TNF- (P0.0002), and IL-10 (P0.014),
were significantly raised in the PAH group as a whole
compared with healthy control subjects. No significant dif-
ference was observed in levels of IL-5, IL-13, or interferon-
compared with healthy control subjects. Details of these
results are presented in Table 2 and Figure 1. Two PAH
patients were not included in the following analyses because
their cytokine levels were 2 orders of magnitude greater
than the mean for the group.
Impact of BMPR2 Mutations on Clinical
Characteristics and Cytokine Levels
Twelve patients had either a proven mutation in BMPR2 or a
family history of PAH, fitting the criteria for heritable PAH.
They were analyzed as a subset. The patients with heritable
Table 1. Baseline Characteristics of All PAH Patients
Control
Subjects
IPAH
Total BMPR2mut BMPR2wt
N 21 58 12 46
Age, y 42.0 (13.0) 48.3 (15.3) 32.6 (10.5)* 52.4 (13.7)
Female:male 3:1 2.4:1 1.4:1 2.8:1
mPAP, mm Hg . . . 48.6 (14.7) 60.2 (12.0)* 48.3 (14.8)
CI, L  min1  m2 . . . 2.0 (0.7) 1.9 (0.4) 2.0 (0.7)
PVR, Wood units . . . 13.4 (7.6) 15.8 (8.5) 13.4 (7.2)
6MWD, m . . . 332 (115) 416 (78)* 308 (113)
*P0.05 versus BMPRwt.
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PAH (known as BMPR2mut) were significantly younger than
the patients free of mutations (BMPR2wt), and their mean
pulmonary artery pressures (mPAPs) were higher (60.212.0
versus 48.314.8 mm Hg; P0.009). There were no signif-
icant differences in either their CIs or PVRs (Table 1). As a
group, heritable PAH patients demonstrated increased levels
of IL-1, IL-2, IL-4, IL-6, IL-8, and IL-10 (Table 2)
compared with control subjects. There was no significant
difference in cytokine levels between the heritable and
BMPR2wt group.
Correlations Between Different Cytokines
Significant correlations were observed between individual
cytokines. For example, levels of IL-8 demonstrated a weak
correlation with TNF- (r0.27, P0.05) and IL-2 (r0.34,
P0.01), whereas IL-6 correlated strongly with levels of IL-8
(r0.94, P0.0001). Full results are shown in Table 3.
Correlations of Cytokine Levels With
Hemodynamic Parameters
For the following analyses, heritable and idiopathic PAH pa-
tients were considered together. The median time from cytokine
sampling to the closest RHC was 3.3 months (interquartile
range, 0.7 to 7.2 months). We sought to determine whether
cytokine levels correlated with the following hemodynamic
parameters: mPAP, cardiac index (CI), and pulmonary vascular
resistance (PVR). There was a negative correlation between IL-8
and CI (r0.26, P0.047; see Table 3). However, there were
no significant correlations between cytokine levels and mPAP or
PVR (data not shown). When patients who had undergone RHC
within 3 months of cytokine sampling were analyzed separately
(n31), there was a significant correlation between TNF- and
CI (r0.39, P0.03). None of the other cytokines demon-
strated any significant correlations with hemodynamic parame-
ters in this subgroup.
Correlations of Cytokine Levels With 6MWD
We next questioned whether any of the cytokines levels
correlated with exercise capacity, as measured by 6MWD.
Only TNF- showed a weak correlation with 6MWD at the
time of sampling (r0.24), although this did not quite
reach significance (P0.07). None of the other cytokines
measured correlated significantly with 6MWD.
Impact of Prostaglandin/Prostanoid Use on
Cytokine Levels
Because the use of prostanoids in PAH has been shown to
suppress levels of some cytokines,16 we investigated the
impact of these agents on circulating cytokine levels in our
population. Of the 58 PAH patients, 30 were on prostanoid
therapy of some kind (ie, epoprostenol, treprostinil, iloprost,
or combinations of the above with agents such as sildenafil).
Compared with the remaining 28 patients, prostanoid users
exhibited significantly higher levels of IL-10 (4.72 versus
2.85 pg/mL in prostanoid-naive patients; P0.05). There
were also higher levels of IL-8 in prostanoid users, but this
Figure 1. Graphs showing the distribution and
medians of serum cytokine levels in PAH patients
and control subjects. Graphs show IL-2, IL-6,
IL-10, and IL-8. Note that axes are split on all
graphs. Statistical significance was determined
with the Mann-Whitney test. *P0.05; **P0.01.
Table 2. Serum Cytokine Levels in PAH Patient Groups Versus
Healthy Control Subjects
Controls
(n21),
pg/mL
IPAH
(n58),
pg/mL
BMPR2mut
(n12),
pg/mL
BMPR2wt
(n46),
pg/mL
IL-1 0.24 (0.05) 0.52 (0.08)† 0.46 (0.10)* 0.54 (0.09)†
IL-2 0.67 (0.08) 1.68 (0.40)† 1.40 (0.22)† 1.76 (0.50)†
IL-4 0.83 (0.07) 1.10 (0.64)* 1.40 (0.23)* 1.02 (0.08)
IL-5 1.37 (0.28) 1.97 (0.30) 2.25 (0.66) 1.89 (0.34)
IL-6 5.70 (0.40) 19.87 (7.45)† 14.56 (3.97)* 21.25 (9.36)†
IL-8 14.30 (1.08) 55.38 (22.18)† 40.04 (11.52)* 59.38 (27.85)†
IL-10 3.83 (1.07) 8.70 (1.66)* 10.00 (3.96)* 8.36 (1.85)*
IL-12 5.62 (1.99) 14.99 (5.42)* 13.85 (5.81) 15.29 (6.69)
IL-13 9.14 (2.58) 16.08 (3.39) 17.03 (6.52) 15.83 (3.95)
Interferon- 1.25 (0.14) 1.64 (0.17) 1.96 (0.36) 1.56 (0.19)
TNF- 7.92 (0.34) 10.45 (0.55)† 9.85 (0.93) 10.61 (0.66)†
All values are expressed as mean (SEM).
*P0.05, †P0.01 versus control subjects.
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did not quite reach significance (26.65 versus 20.7 pg/mL in
prostanoid-naive patients; P0.075).
Correlations of Cytokine Levels With
Survival Time
Kaplan-Meier analyses were undertaken for all significantly
elevated cytokines for 57 of the 58 patients (1 patient had
emigrated and was lost to follow-up). At the time of censor-
ing, 25 patients had died without undergoing transplantation,
and 5 had been transplanted. It was possible to stratify PAH
patients into groups with significantly better and worse
cumulative survival on the basis of levels of IL-2,IL-6, IL-8,
IL-10, and IL-12p70.
Initially, Kaplan-Meier curves were constructed through
the use of the 4-quartile groups for each cytokine (Figure 2)
and clinical parameter (Figure 3). The most discriminating
survival curves were observed for IL-6, IL-8, IL-10, and
IL-12p70. For example, the 1-year survival for patients in the
Table 3. Analysis of Correlations Between Significantly Elevated Cytokines in
PAH Patients
CI IL-1 IL-2 IL-6 IL-8 IL-10 IL-12 TNF-
0.05 0.04 0.19 0.20 0.27* 0.20 0.15 CI
0.31* 0.14 0.12 0.30* 0.20 0.22 IL-1
0.28* 0.33† 0.22 0.21 0.17 IL-2
0.94‡ 0.32* 0.09 0.24 IL-6
0.26 0.04 0.27* IL-8
0.66† 0.09 IL-10
0.06 IL-12
TNF-
Correlation coefficients are determined by the Spearman method.
*P0.05, †P0.01, ‡P0.001.
Figure 2. Kaplan-Meier analyses based on cytokine levels in PAH patients. Graphs show survival curves based on levels of IL-10, IL-8,
IL-12, and IL-6. Note that these analyses were performed on 57 of 58 patients; 1 patient was lost to follow-up.
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first quartile for IL-10 values was 100%, whereas the corre-
sponding 1-year survival for patients in the fourth quartile was
71.4%. At 5 years, the cumulative survival for patients in the
first quartile was 71.4%, whereas the cumulative survival for
patients in the fourth quartile was 14.3%. The log-rank P value
for comparing the 4-group curves for IL-10 was 0.002. For
IL-12p70, the 1-year and 5-year cumulative survival rates for
patients in the first quartile were 100% and 77.0%, whereas the
1-year and 5-year cumulative survival rates for patients in the
fourth quartile were 64.3% and 28.6% (log-rank P0.038).
In addition, we undertook a 2-group survival comparison
based on a single cytokine level that provided the largest
difference in survival curves. For example, the 1-year cumu-
lative survival for patients with IL-10 5 pg/mL was 92.3%,
whereas it was 72.2% for patients with IL-10 levels of 5
pg/mL. These differences became more pronounced at 5
years, when the cumulative survival rates were 63.0% and
17.3%, respectively (P0.001). A similar pattern was seen
for IL-8; a serum level of 30 pg/mL was associated with a
1-year cumulative survival of 94.6%, whereas patients with a
serum level of 30 pg/mL had a 1-year cumulative survival
of 70.0%. The 5-year cumulative survival rates were 57.6%
and 32.0%, respectively (P0.005). PAH patients with levels
of IL-69 pg/mL had 1- and 5-year cumulative survival rates
of 93.9% and 62.8%, respectively, whereas patients with
levels 9 pg/mL had 1- and 5-year survival rates of 75.0%
and 29.6% (P0.008). PAH patients with levels of IL-12p70
of 7 pg/mL had 1- and 5-year cumulative survival rates of
92.3% and 61.3%, respectively, whereas IL-12p70 levels
of 7 pg/mL had 1- and 5-year cumulative survival rates of
72.2% and 20.7% (P0.014). These results are summarized
in Table 4. Using the c index as another approach to
determine the most discriminating level of each cytokine as a
predictor of survival gave results very similar to the above
analysis, except for IL-12, for which the median value of 3.85
pg/mL improved survival prediction slightly.
Kaplan-Meier analyses were also performed using classic
parameters affecting prognosis, including hemodynamics de-
rived from RHC (for all patients) and 6MWD (for 53 of 57
patients because 4 patients were unable to perform a 6MWD).
First, we analyzed the relationship between hemodynamic
parameters and survival using an approach similar to that
used to determine cutoff levels of individual cytokines based
on interpolation between the median and quartile values. By
this analysis, a CI of 2 L  min1  m2 and an mPAP of
50 mmHg proved to be significant discriminators for
Figure 3. Kaplan-Meier analyses based on traditional clinical parameters in PAH patients. Graphs show survival curves based on
mPAP, CI, PVR, and 6MWD. Note that the analysis for the 6MWD graph was based on 53 of the 57 patients; 4 patients were unable to
perform a 6MWD.
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survival. Patients with a CI of 2 L  min1  m2 had 1- and
5-year cumulative survival rates of 87.9% and 35.3%, respec-
tively, whereas those with a CI2 L  min1  m2 had 1- and
5-year cumulative survival rates of 87.5% and 66.8%
(P0.04). Patients with an mPAP of 50 mmHg had 1- and
5-year cumulative survival rates of 80.8% and 40.0%, respec-
tively, and those with an mPAP of 50 mmHg had 1- and
5-year cumulative survival rates of 93.5% and 54.5%
(P0.044). A 6MWD of330 m gave the best separation of the
curves, but differences were not significant (P0.07). Similarly,
the optimal value for PVR did not achieve significant separation
of the survival curves. We further analyzed 6MWD, mPAP, and
CI based on predictive cutoff values reported in the literature. By
this analysis, neither a 6MWD of 332 m (based on work by
Miyamoto et al17) nor an mPAP of65 mm Hg (based on work
by Sitbon et al18) proved to be a significant discriminator for
survival. Our cutoff value of CI (2 L  min1  m2) was
identical to that determined by d’Alonzo et al.19
To further determine whether there was any contribution of
hemodynamics to the ability of cytokine levels to predict
survival, we analyzed hemodynamics in patients with “low”
and “high” levels of IL-2, IL-6, IL-8, IL-10, and IL-12p70,
broken down according to the most discriminatory cytokine
levels used in the Kaplan-Meier analyses. There were no
significant differences in mPAP, CI, or PVR for patients with
either low or high levels of IL-2, IL-6, IL-8, and IL-12p70.
However, for IL-10, the mean CI was higher in patients with
low levels of IL-10 (2.120.67 L/min2) than in patients with
high levels (1.670.34 L/min2; P0.003). Using a Cox
proportional-hazards model, we found that the additional
consideration of hemodynamic indices did not significantly
improve the predictive power of cytokine levels (Table I in
the online-only Data Supplement). The addition of cytokine
levels to a Cox model based on hemodynamic parameters did
not significantly improve survival predictions based on he-
modynamics (Table II in the online-only Data Supplement).
Discussion
This study is the first to simultaneously profile a broad range
of cytokines in patients with idiopathic and heritable PAH.
Our results indicate a significant dysregulation in levels of
inflammatory cytokines in IPAH patients. Consistent with
previous studies, we observed significantly elevated levels of
IL-1, IL-6, and TNF-.4,5 In addition, we demonstrated that
the dysregulation of serum cytokines in PAH is more exten-
sive than previously recognized and includes significantly
increased serum levels of IL-2, IL-4, IL-8, IL-10, and
IL-12p70 compared with normal control subjects.
A major strength of this study was the long-term follow-up
of PAH patients at our center after serum cytokine measure-
ment. This resource allowed us to assess for the first time the
impact of a range of serum cytokines on survival. We have
demonstrated that levels of IL-2, IL-6, IL-8, IL-10, and
IL-12p70 were predictors of survival in this cohort. Further-
more, serum cytokine levels were more closely related to
survival than classic indexes of right heart function measured
at RHC and performed better than the widely used 6MWD.
There was a lack of correlation between levels of cytokines
and hemodynamic parameters as measured by RHC. This is
interesting because it may mean that cytokines are potentially
involved in the pathogenesis of PAH and are not just a
reflection of right ventricular function. An earlier study by
Humbert et al4 that examined IL-1 and IL-6 levels in 29
patients with IPAH also did not show any correlation between
cytokine levels and hemodynamic parameters.
Our study does not directly address the mechanism and
pathological role of increased cytokines in PAH. Inflamma-
tion and inflammatory cytokines such as IL-6 and IL-8 may
be an important part of the initial response to injury contrib-
uting to the process of vascular remodeling in PAH. Elevated
levels of antiinflammatory cytokines such as IL-10 may serve
as compensatory mechanisms. The patients in our population
were on various approved treatments for PAH, often in
combination. Almost half of the patients were on prostanoid
therapy. A previous study has shown that administration of
epoprostenol led to a significant decline in elevated circulat-
ing levels of monocyte chemoattractant protein-1 in PAH
patients.20 In our PAH population, prostanoids did not ame-
liorate the elevated cytokine levels observed in PAH patients.
Indeed, there was a trend toward an increase in IL-10 and
IL-8. We suspect that this was due to the presence of more
advanced disease. Because prostanoids are indicated for
severe disease, it is consistent with our findings that elevated
levels of IL-10 and Il-8 are found in patients prescribed
prostanoids.
Animal studies strongly support a pathological role for
IL-6 in PAH. Overexpression of IL-6 induces PAH and
vascular remodeling in rodents and further augments
Table 4. Cumulative Survival at 1-, 3-, and 5-Year Periods
Based on Cytokine Levels and Classic Parameters
Cytokine
1-y
Cumulative
Survival, %
3-y
Cumulative
Survival, %
5-y
Cumulative
Survival, %
Log-Rank
P
IL-1 0.50 pg/mL 83.8 61.9 51.3 0.675
IL-1 0.50 pg/mL 90.0 58.3 43.7
IL-2 1.50 pg/mL 88.4 69.4 56.0 0.021*
IL-2 1.50 pg/mL 78.6 35.7 28.6
IL-6 9.00 pg/mL 93.9 75.8 62.8 0.008†
IL-6 9.00 pg/mL 75.0 41.7 29.6
IL-8 30.0 pg/mL 94.6 72.5 57.6 0.005†
IL-8 30.0 pg/mL 70.0 40.0 32.0
IL-10 5.00 pg/mL 92.3 79.5 63.0 0.001†
IL-10 5.00 pg/mL 72.2 25.9 17.3
IL-12 7.00 pg/mL 92.3 71.4 61.3 0.014*
IL-12 7.00 pg/mL 72.2 38.9 20.7
TNF- 12.0 pg/mL 86.8 59.5 51.0 0.879
TNF- 12.0 pg/mL 84.2 63.2 47.4
mPAP 65 mmHg 87.2 59.0 50.3 0.887
mPAP 65 mmHg 90.0 68.6 34.3
CI 2 L  min1  /m2 87.9 47.0 35.3 0.042*
CI 2 L  min1  /m2 87.5 79.2 66.8
6MWD 332 m 81.5 55.3 46.1 0.125
6MWD 332 m 96.2 72.3 54.7
*P0.05, †P0.01.
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hypoxia-driven pulmonary hypertension.8–10 Interestingly,
levels of IL-6 have a significant impact on survival despite
having no significant correlation with hemodynamic param-
eters or exercise tolerance. Additionally, IL-8 levels corre-
lated only weakly with CI. Previous studies support a wider
role for IL-6 and IL-8 than modulation of immune re-
sponses. Indeed, IL-6 and IL-8 have been demonstrated to
modulate smooth muscle and endothelial cell function and
are strongly implicated in vascular remodeling.21–25 Further-
more, Brock et al12 recently described a novel pathway by
which IL-6 can affect micro-RNAs and signaling via BMPR-
II. Collectively, these studies support the notion that IL-6 and
IL-8 can directly affect vascular remodeling.
The increased levels of the antiinflammatory cytokine
IL-10 observed in patient sera may represent a compensatory
mechanism antagonizing the inflammatory response. Adeno-
viral expression of IL-10 protects against monocrotaline-
induced pulmonary hypertension in rats.13 Furthermore,
IL-10 is a potent immunomodulator that inhibits the secretion
of various proinflammatory cytokines, including IL-6 and
IL-8.13,26 Collectively, this supports the notion that elevated
serum levels of IL-10 in IPAH patients represent a compen-
satory mechanism to prevent inflammatory cell infiltration,
chemokine expression, and smooth muscle cell proliferation.
Studies to define the precise mechanisms by which these
inflammatory cytokines act in vivo are currently ongoing.
Consistent with previous studies, we found IL-1 to be
elevated in patient serum. Circulating levels of IL-2, like
IL-1, are also elevated in chronic left heart failure. A major
role for IL-2 is to promote T-cell proliferation. Indeed,
infusion of recombinant IL-2 has been used to treat some
cancers. A noted side effect of this treatment is pulmonary
edema. Administration of IL-2 in animal studies has demon-
strated that IL-2 promotes pulmonary edema via enhanced
vascular permeability. These same studies noted that IL-2
promoted vasoconstriction and pulmonary hypertension.27,28
Although the pathological mechanisms by which IL-2 pro-
motes these effects remains unclear, IL-2 induces expression
of endothelin-1, a key pathological factor in IPAH.29
Elevated TNF- in serum has previously been shown to
correlate with mortality in left heart failure patients.30 Sur-
prisingly, levels of TNF-, although significantly elevated in
IPAH patients, did not correlate with survival or hemody-
namic parameters in our cohort. Recent anti–TNF- trials in
heart failure patients failed to demonstrate efficacy,31,32 sug-
gesting a more complex role for TNF-. One potential
limitation of the present study is that hemodynamic data
sampling and serum collection did not coincide in some of
our patients. The median time from cytokine sampling to
RHC was 3.3 months. However, when we analyzed only
those patients in whom sampling and RHC occurred within 3
months of each other, we did find a significant correlation
between CI and TNF-. No other cytokine showed a corre-
lation with hemodynamics in this subgroup.
The strong impact of circulating levels of IL-6, IL-8, and
IL-10 on mortality suggests that these cytokines may prove to
be important tools in risk stratifying IPAH patients. In this
particular cohort, cytokine levels appeared to be more useful
than traditional parameters such as hemodynamics and
6MWD. Focused studies to define the temporal changes of
these cytokines during disease progression and treatment are
now warranted. Finally, the finding that elevated levels of
cytokines have an impact on mortality supports the need for
further studies to define the potential for targeting these
cytokines for therapeutic intervention in PAH.
Conclusions
The present study identifies, for the first time, elevated serum
levels of IL-2, IL-4, IL-8, IL-10, and IL-12p70 in patients
with idiopathic and familial PAH. We have also confirmed
that IL-1, IL-6, and TNF- are elevated in PAH, confirming
the results of previous smaller studies. Circulating levels of
IL-2, IL-6, IL-8, IL-10, and IL-12p70 had a significant
impact on survival and may prove to be important biomarkers
in risk stratifying these patients.
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CLINICAL PERSPECTIVE
Inflammation is known to be a feature of pulmonary arterial hypertension (PAH), and increased circulating levels of cytokines
have been reported in patients with PAH. A significant number of animal studies have also highlighted the importance of
cytokines in the pathogenesis of PAH. However, to date, no information exists on the significance of elevated cytokines. We
sought to determine the levels of a range of cytokines in PAH and to examine their impact on survival and their relationship to
hemodynamic indexes. We measured levels of tumor necrosis factor-, interferon-, and interleukins-1, -2, -4, -5, -6, -8, -10,
-12p70, and -13 using ELISAs in idiopathic and heritable PAH patients. Concurrent clinical data included hemodynamics,
6-minute walk distance, and survival time from sampling to death or transplantation. PAH patients had significantly higher levels
of interleukin-1, -2, -4, -6, -8, -10, and -12p70 and tumor necrosis factor- compared with healthy control subjects.
Kaplan-Meier analysis showed that levels of interleukin-6, -8, -10, and -12p70 predicted survival in patients. For example, 5-year
survival with interleukin-6 levels of 9 pg/mL was 30% compared with 63% for patients with levels 9 pg/ml (p0.008). In
this cohort, cytokine levels were superior to traditional markers of prognosis such as hemodynamics. This study illustrates
dysregulation of a broad range of inflammatory mediators in idiopathic PAH and demonstrates that cytokine levels have a
previously unrecognized impact on patient survival. They may prove to be useful biomarkers of prognosis once validated
prospectively. They may also provide insight into the contribution of inflammation in PAH.
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Supplementary Table 1: Cox regression modeling based on cytokine levels with the 
addition of hemodynamic parameters 
 
  Parameter  Parameter + Parameter + Parameter + Parameter + 
  alone mPAP cardiac index PVR 
mPAP + CI + 
PVR
IL-2      
HR (per pg/ml) 1.098 1.104 1.083 1.094 1.091
95% CI 1.012-1.190 1.016-1.200 0.999-1.175 1.007-1.189 1.003-1.186
p-value 0.025* 0.019* 0.054 0.033* 0.042*
       
IL-6      
HR (per pg/ml) 1.005 1.005 1.004 1.005 1.004
95% CI 1.000-1.009 1.001-1.010 0.999-1.008 1.000-1.009 1.000-1.009
p-value 0.038* 0.029* 0.084 0.049* 0.055
       
IL-8      
HR (per pg/ml) 1.002 1.002 1.001 1.002 1.001
95% CI 1.000-1.003 1.000-1.003 1.000-1.003 1.000-1.003 1.000-1.003
p-value 0.035* 0.028* 0.081 0.044* 0.062
       
IL-10      
HR (per pg/ml) 1.025 1.026 1.022 1.025 1.023
95% CI 1.003-1.047 1.004-1.048 0.99-1.044 1.002-1.048 0.999-1.047
p-value 0.025* 0.021* 0.056 0.035 0.063
       
mPAP      
HR (per mmHg) 0.991 - 0.978 0.974 0.973
95% CI 0.966-1.016 - 0.950-1.007 0.940-1.009 0.937-1.011
p-value 0.472 - 0.14 0.14 0.163
       
Cardiac index      
HR (per 
l/min/m2) 0.495 0.42 - 0.424 0.457
95% CI 0.232-1.057 0.193-0.912 - 0.171-1.054 0.193-1.082
p-value 0.069 0.028* - 0.065 0.075
       
PVR      
HR (per Wood 
unit) 1.013 1.045 0.982 - 1.015
95% CI 0.968-1.060 0.986-1.108 0.928-1.040 - 0.946-1.088
p-value 0.569 0.142 0.535 - 0.682
 
Key:  
*p<0.05 
HR: hazard ratio 
CI: confidence intervals 
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Supplementary Table 2: Cox regression modeling based on hemodynamic parameters 
with additional cytokine parameters 
 
 
 Parameter  Parameter + Parameter + Parameter + Parameter + 
 alone IL-6 IL-8 IL-10 IL-12
         
mPAP      
HR (per mmHg) 0.991 0.988 0.989 0.989 0.991
95% CI 0.996-1.016 0.963-1.014 0.963-1.015 0.963-1.015 0.965-1.016
p-value 0.472 0.370 0.396 0.384 0.468
       
Cardiac index      
HR (per 
l/min/m2) 0.495 0.526 0.532 0.528 0.493
95% CI 0.232-1.057 0.246-1.124 0.242-1.169 0.247-1.130 0.231-1.054
p-value 0.069 0.097 0.116 0.100 0.068
       
PVR      
HR (per Wood 
unit) 1.013 1.009 1.009 1.003 1.013
95% CI 0.968-1.060 0.963-1.058 0.963-1.058 0.955-1.053 0.968-1.060
p-value 0.569 0.701 0.694 0.915 0.571
 
 
 
 
HR: hazard ratio 
CI: confidence intervals 
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